By Lisa Kerner
Erie, Pa., Feb. 21 - Supernus Pharmaceuticals, Inc., said it has closed a second round of $17.5 million series A financing, completing its series A funding for a total of $45 million in venture capital.
The company announced last month the closing of the first round of financing and the acquisition of substantially all the assets comprising the product formulation and development business of Shire Laboratories Inc., a subsidiary of Shire plc.
Investors participating in this second closing were New Enterprise Associates and Abingworth Management.
Michael Bigham, a director of Abingworth, will join the Supernus' board of directors.
Located in Rockville, Md., Supernus is a specialty pharmaceuticals company that has a portfolio of proven and patented drug delivery technologies with full product development capabilities including production of GMP clinical supplies in its own facility.
| Issuer: | Supernus Pharmaceuticals, Inc.
|
| Issue: | Series A venture capital
|
| Amount: | $17.5 million
|
| Investors: | New Enterprise Associates, Abingworth Management
|
| Announcement date: | Feb. 21
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
